Abstract:Background: Recent advances in the understanding of the molecular mechanisms underlying atopic dermatitis (AD) and psoriasis (PSO) have led to the development of multiple targeted therapies. Yet, molecular heterogeneity contributes to inconsistent clinical presentation and therapeutic response. Further, systemic treatment of presumed AD or PSO can lead to delays in both diagnosis and proper treatment of patients with a true diagnosis of mycosis fungoides (MF) – a potentially dangerous clinical mimic of AD and PSO that requires a rigorous histologic and molecular workup to diagnose. Therefore, a non-invasive method to distinguish molecular profiles of MF from AD and PSO could inform accurate diagnoses and avoid inappropriate treatment of MF. We have previously shown transcriptomic differences in AD and PSO samples obtained by a non-invasive scraping technique. However, this technique has not been used to assess differences in gene expression profiles of MF samples. Objectives: To identify gene expression differences based on diagnosis of MF, AD, or PSO and response to targeted systemic AD or PSO therapies. Methods: Lesional baseline samples were assessed from 76 patients (AD, n=24; PSO, n=48; and MF, n=4) enrolled in one of two IRB-approved studies (IDENTITY or SIGNAL-MF). Lesional samples were collected by epidermal scraping and preserved in RNA buffer. Library preparation and next generation RNA sequencing was performed using the Ion AmpliSeq Transcriptome Human Gene Expression panel on the S5 Prime sequencer (ThermoFisher). Clinical responses for AD and PSO were further assessed over 3 months using the eczema and psoriasis area and severity index (EASI and PASI, respectively). Genes were considered differentially expressed if there was a log2fold change >|1.0| and padj <.05. Results: Statistically significant differences in gene expression were observed between AD, PSO, and MF lesions. Further, genes were differentially expressed in baseline skin scrapings obtained from super-responders to dupilumab, which blocks both IL-4 and IL-13 signaling, and PSO therapies including the IL-23 inhibitor risankizumab relative to those who did not achieve ≥90% improvement. Conclusion: A non-invasive molecular test could be developed to distinguish between AD, PSO, and MF, and further identify super-responders to targeted PSO and AD therapies.

Immunophenotyping comparison of inflammatory cells between <i>Malassezia</i> folliculitis and pityriasis versicolor lesions

Immuohistochemical Comparison of Infiltrating Cells among Mycosis Fungoides, Lichen Planus and Psoriasis

COMPARATIVE ANALYSIS OF IMMUOHISTOLOGICAL FEATURES AMONG MYCOSIS FUNGOIDES,LICHEN PLANUS AND ECZEMATOUS DERMATITIS

[Yeast-like fungi malassezia (pityrosporum): clinical and immunological aspects fo study]

Molecular identification of Malassezia from the skin scrapings of clinically suspected cases of pityriasis versicolor

Similar but different: distinguishing between pemphigus vegetans and pyostomatitis-pyodermatitis vegetans

Comparison of serum cytokines and chemokines levels and clinical significance in patients with pemphigus vulgaris—A retrospective study

A case of anti- pityriasis versicolor therapy that preserves healthy mycobiome

Biophysical and ultrasonographic changes in early patch/plaque stage of mycosis fungoides, compared with uninvolved skin

547 A Variant Subtype of Psoriasis with a Unique Clinical and Immunological Characteristics

Molecular Markers of Early-Stage Mycosis Fungoides

Molecular Epidemiology, in Vitro Susceptibility and Exoenzyme Screening of Malassezia Clinical Isolates

Mycosis Fungoides Exhibits a Th1-Type Cell-Mediated Cytokine Profile Whereas Sezary Syndrome Express a Th2-Type Profile

Pigmented purpuric dermatoses versus purpuric mycosis fungoides: Clinicopathologic similarities and new insights into dermoscopic features

When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses

CD4+ T-cell Subsets and Cytokine Signature in Pemphigus Foliaceus Clinical Stratification beyond the th1/Th2 Paradigm

Malassezia species in skin diseases

Dermoscopic Features of Mycosis Fungoides and Its Variants in Patients with Skin of Color: A Retrospective Analysis

Comparison of gut microbiota dysbiosis between pemphigus vulgaris and bullous pemphigoid

Immunology of Diseases Associated with Malassezia Species

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis